The fight against neurodegenerative diseases, Alzheimer disease and Parkinson's disease
(PD), is a challenge of the 21st century. The low efficacy of treating patients is due to the late …

Modeling and simulation in general, and specifically clinical trial simulation (CTS), have
been recognized by the (larger) pharmaceutical companies and regulatory authorities as …

Pharmacometric modeling establishes causal quantitative relationship between
administered dose, tissue exposures, desired and undesired effects and patient's risk …

Since the inception of CEST MRI in the 1990s, a number of compounds have been identified
as suitable for generating contrast, including paramagnetic lanthanide complexes …

Glucose is a monosaccharide sugar that our bodies obtain from food and use as our
principal energy source.[1] The basic molecular form of glucose is C 6 H 12 O 6. The sugar …

Optimization of clinical trial designs can help investigators achieve higher quality results for
the given resource constraints. The present paper gives an overview of optimal designs for …

Abstract Model‐based design of experiments (MBDOE) assists in the planning of highly
effective and efficient experiments. Although the foundations of this field are well …

The integrated glucose‐insulin model was originally developed on a variety of intravenous
glucose provocation experiments in healthy volunteers and type 2 diabetic patients. The …

Being able to scale preclinical pharmacodynamic response to clinical would be beneficial in
drug development. In this work, the integrated glucose insulin (IGI) model, developed on …

The integrated glucose‐insulin (IGI) model is a previously published semimechanistic model
that describes plasma glucose and insulin concentrations after glucose challenges. The aim …